OR WAIT null SECS
These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.
Guselkumab (Tremfya) may lead to significant and rapid improvements in moderate-to-severe scalp psoriasis clearance among patients with skin of color, according to newly-announced findings, as well as improvements in health-related quality of life and post-inflammatory pigmentation.1
These phase 2b findings on guselkumab were announced by Johnson & Johnson on January 22, having resulted from the VISIBLE study and having been presented at the Maui Derm Hawaii 2024 conference. Guselkumab is the first IL-23 inhibitor approved in the US for adult psoriasis patients who qualify for systemic therapy or for phototherapy.
The VISIBLE study represents the inaugural prospective, large-scale, randomized-controlled trial on guselkumab designed for individuals of diverse skin tones, specifically, who are experiencing plaque psoriasis and scalp psoriasis. The study had been designed to objectively examine outcomes related to both clearance and other measures using guselkumab.
"Scalp psoriasis is highly prevalent and can present unique challenges across diverse populations,” Andrew Alexis, MD, MPH, professor of clinical dermatology at Weill Cornell Medicine and lead study investigator, said in a statement. “In patients of color, cultural factors related to hair care practices and post-inflammatory pigment changes contribute to the burden of scalp psoriasis. These findings from VISIBLE are key to broadening our understanding of scalp psoriasis, and the role (guselkumab) can have in treating all patients with this disease.”
The study’s clinical program was designed to gather more than 20,000 clinical images spanning various types of skin tones. This may help to promote improved disease recognition as well as education among both psoriasis patients and among healthcare providers.
There were 3 posters highlighting these new findings, one of which was titled 'Guselkumab Significant and Rapid Scalp Clearance Data at Week 16.’ This poster showed the following:
In the second poster, titled 'Guselkumab Patient-Reported Health-Related Quality of Life (HRQoL) Improvements' the following findings were highlighted:
The third poster highlighted in the announcement looked at data surrounding post-inflammatory pigment alteration (PIPA), which is noted as skin discoloration which may result from either inflammation or injury and is a part of conditions such as psoriasis. This is particularly the case among those with melanin-enriched skin.
In this poster, titled 'Guselkumab Patient-Reported Post-Inflammatory Pigmentation Data,' the following highlighted findings were included:
In October 2023, this study had introduced Cohort A which had aimed at patients with skin-predominant psoriasis that also came from diverse ethnic backgrounds. Along with the recent discoveries seen in Cohort B, the research may lead to improved understanding of this patient population.
"The VISIBLE study will continue to generate insights and data that may help clinicians improve the disease journey and health outcomes for people of color with skin and scalp plaque psoriasis who have historically been undertreated and underrepresented in clinical research and in medical education,” Alexis said in a statement.